Plus Therapeutics has received FDA approval to start the ReSPECT-LM dose optimization trial for its drug, REYOBIQ™, aimed at treating leptomeningeal metastases. The trial’s primary goal is to establish the optimal dosing schedule for a future registrational trial. This new study builds on the recommended Phase 2 dose identified in a completed Phase 1 trial. The initiative benefits from a $17.6 million award, which will support the trial’s execution. This development marks a significant step in advancing treatment options for patients with this challenging condition, potentially improving outcomes and expanding therapeutic possibilities.
Leave a Reply